此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估Croma Revitalis用于改善细纹的非干预性上市后临床随访研究 (RICHER)

2026年10月31日 更新者:Croma-Pharma GmbH

一项非干预性、上市后临床随访(PMCF)、前瞻性、开放标签、单中心观察性研究,评估Croma Revitalis在改善细纹方面的效果

This study will serve to collect and analyze additional data on the use of the device croma revitalis for treatment of fine lines on the face including LCL and PR in the routine practice and as "real-world" performance.

研究概览

地位

完全的

详细说明

This study is designed to observe the effects of croma revitalis, a medical device used to improve fine lines and skin quality, under real-life conditions. It is a prospective, open-label, non-comparative study, meaning all participants will receive the treatment, and both doctors and participants know what is being administered. This setup allows for efficient collection of clinical data while reflecting typical use in aesthetic practice. The study aims to evaluate improvements in skin concerns such as loss of volume, moisture, tone, and elasticity. The main way effectiveness will be measured is through the Global Aesthetic Improvement Scale (GAIS). This is a widely accepted 5-point scale used by doctors to assess visible improvements after treatment. The focus will be on improvements in areas such as lateral canthal lines (LCL), commonly known as "crow's feet", and perioral rhytides (PR), often referred to as "smile lines" or "smoker's lines." The primary evaluation point is Week 8, which is a typical follow-up period after a full treatment cycle consisting of three applications of the product. Participants will continue to be monitored until Week 24. The study plans to enroll approximately 70 participants, with the goal of collecting complete Week 8 data from at least 55 individuals.

研究类型

观察性的

注册 (实际的)

71

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adults seeking aesthetic treatment for fine lines, such as crow's feet and smile lines. Participants will be generally healthy and representative of typical dermal filler users in routine clinical practice.

描述

Inclusion Criteria:

  • Participants deemed by the treating physician to have LCL and/or PR of sufficient severity to merit treatment with croma revitalis to be corrected and treatment decision is reached independent of this study.
  • Male or female, 18 years of age or older at Visit 1 (Day 0).
  • Healthy skin in the facial area and free of diseases that could interfere in cutaneous aging evaluation, based on the physician's judgment.
  • Participants who, according to routine clinical advice, are willing to refrain from undergoing any aesthetic or surgical procedures in the treatment area during the observation period.
  • Participants who understand the purpose and nature of the observational data documentation and willingness to participate in the routine follow-up after 3, 5, 8, 12, and 24 weeks as judged by the treating physician.
  • Written signed and dated informed consent.

Exclusion Criteria:

  • Participants who tend to develop hypertrophic scars, have pigment disorders, or have susceptibility to keloid formation.

  • Participants with a history of autoimmune disease or who are receiving therapy for modification of immune response, e.g., biologics, systemic corticosteroids, cytostatic drugs (from Visit 1 [Day 0] until the end of the study).

  • Participants who are known to be hypersensitive to components of the device as HA, glycerol, or gram-positive bacterial proteins.

  • Participants who are pregnant or breast feeding.

  • Participants who are anticoagulated or with history of bleeding disorder.

  • Participants receiving daily treatment with platelet aggregation inhibitors (e.g., acetylsalicylic acid) unless previously cleared by their primary care physician.

  • Participants who have cutaneous, inflammatory, and/or infectious processes (e.g., acne, herpes) present at Visit 1 (Day 0), recurrent herpes simplex or (pre) cancerous lesions in the areas to be treated.

  • Previous permanent implant or treatment with non-HA or non-collagen filler or non-absorbable sutures in the treatment area(s) any time prior to or planned during the observation period.

  • Participants who have received dermabrasion, mesotherapy, chemical peeling, or micro-needling within 3 months prior first treatment and planned during the observation period.

  • Participant has received any of the following (aesthetic) treatments in the treatment area within the last 12 months prior to the first routine treatment or planned during the observation period:

    1. Energy based device treatments that target collagen remodeling and/or production of collagen (e.g. laser therapy).
    2. Absorbable sutures (threads).
    3. HA or collagen dermal fillers.
    4. Botulinum toxin treatment.
    5. Facial lipolysis, including submental fat treatments.
    6. Facial plastic surgery.
    7. Bariatric surgery.
  • Participants with uncontrolled (or unstable) systemic diseases as per the treating physician's discretion.

  • Prior surgery, scars, or tattoos in the treatment area(s), that could interfere with clinical evaluation. Participants planning such procedures during the observation period will not be included.

  • Beard, or facial hair that could interfere in evaluation of treatment as judged by the physician.

  • Participants who have had or are planning to undergo bariatric surgery or facial plastic surgery in the area to be treated within less than 12 months before the first treatment in and planned during the observation period.

  • Planned dental/oral surgery or modification (bridge-work, implants) within 4 weeks before the first treatment in and planned during the observation period.

  • Current participation in another clinical study, or treatment with any investigational drug/MD/device within 30 days prior to the first treatment.

  • Any medical condition or treatment potentially interfering with the clinical evaluation, according to the judgment of the treating physician.

  • Participants whose participation in clinical trials is prohibited by the Austrian Medical Devices Act (MPG) (e.g., persons with a legal custodian appointed due to mental disability, prisoners, soldiers, and other members of the armed forces, civil servants).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:OTHER
  • 时间观点:PROSPECTIVE

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Responder status at Week 8 after initial treatment.
大体时间:8 weeks after initial treatment

Visible aesthetic changes at Week 8 after initial treatment in the treated fine lines of at least one treatment area (LCL and/or PR), compared to baseline, as assessed by the physician using the Global Aesthetic Improvement Scale (GAIS). The GAIS is a 5-point scale ranging from 1 (very much improved) to 5 (worse), where lower scores indicate greater aesthetic improvement.

8 weeks after initial treatment

次要结果测量

结果测量
措施说明
大体时间
Responder Status Based on the Global Aesthetic Improvement Scale (GAIS) - Physician Assessment
大体时间:Weeks 3, 6, 12, and 24 after initial treatment

Visible aesthetic changes at Weeks 3, 6, 12, and 24 after initial treatment compared to baseline, as assessed by the physician using the Global Aesthetic Improvement Scale (GAIS).

The GAIS is a 5-point scale ranging from 1 (very much improved) to 5 (worse), where lower scores indicate greater aesthetic improvement. Responders are defined as participants with a GAIS score of 1 (very much improved) or 2 (much improved).

Weeks 3, 6, 12, and 24 after initial treatment
Responder Status Based on the Global Aesthetic Improvement Scale (GAIS) - Independent Evaluator Panel
大体时间:Weeks 3, 6, 12, and 24 after initial treatment

Visible aesthetic changes at Weeks 3, 6, 12, and 24 after initial treatment compared to baseline, as assessed by an independent evaluating panel using the Global Aesthetic Improvement Scale (GAIS).

The GAIS is a 5-point scale ranging from 1 (very much improved) to 5 (worse), where lower scores indicate greater aesthetic improvement. Responders are defined as participants with a GAIS score of 1 (very much improved) or 2 (much improved).

Weeks 3, 6, 12, and 24 after initial treatment
Change in Skin Hydration from Baseline Measured by Corneometer
大体时间:Week 3, 6, 8, 12, and 24

Change in skin hydration compared to baseline measured using a Corneometer device, which quantifies skin hydration on the treated area(s). Higher values indicate greater skin hydration.

Week 3, 6, 8, 12, and 24
Change in Skin Tone from Baseline Measured by Cutometer
大体时间:Week 3, 6, 8, 12, and 24

Change in skin tone compared to baseline measured on the treated area(s) using the Cutometer device.

Week 3, 6, 8, 12, and 24
Change in Skin Elasticity from Baseline Measured by Cutometer
大体时间:Week 3, 6, 8, 12, and 24

Change in skin elasticity compared to baseline measured using a Cutometer device, which assesses the mechanical properties of the skin through suction-based deformation parameters.

Higher values indicate improved skin elasticity.

Week 3, 6, 8, 12, and 24
Participant Satisfaction with Treatment
大体时间:Week 8, 12, and 24

Participant-reported satisfaction with treatment at each specified visit using a 5-point scale: "Very unsatisfied," "Unsatisfied," "Neither unsatisfied nor satisfied," "Satisfied," or "Very satisfied."

Week 8, 12, and 24
Aesthetic change based on the physician's live assessment
大体时间:Week 8, 12 an 24

A live-assessment of the treated areas will be performed and the treated areas will be compared to the participant's photographs obtained at the baseline visit. The presence of the aesthetic change will be recorded as either "Yes" or "No".

Week 8, 12 an 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月16日

初级完成 (实际的)

2026年6月9日

研究完成 (实际的)

2026年10月1日

研究注册日期

首次提交

2026年3月11日

首先提交符合 QC 标准的

2026年3月23日

首次发布 (实际的)

2026年3月25日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月31日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅